← FDA DRUG APPROVALS

FDA ANDA · ANDA201893

NADOLOL

Sponsor: AUROBINDO PHARMA

APPLICATION
ANDA201893
TYPE
ANDA
ORIGINAL APPROVAL
2015-09-16
LATEST ACTION
2024-03-01
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Prescription

Products

NADOLOLPrescription
NADOLOL 80MG · TABLET · ORAL
NADOLOLPrescription
NADOLOL 20MG · TABLET · ORAL
NADOLOLPrescription
NADOLOL 40MG · TABLET · ORAL

Approval history

2024-03-01Labeling · Supplement 7 · standardAP
2022-06-07Manufacturing (CMC) · Supplement 3 · unknownAP
2019-05-01Manufacturing (CMC) · Supplement 1AP
2015-09-16Not Applicable · OriginalLetterAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →